12/2
12:37 am
axsm
Axsome Therapeutics (AXSM): Evaluating Valuation Following Recent Share Price Momentum and Pipeline Expansion [Yahoo! Finance]
Medium
Report
Axsome Therapeutics (AXSM): Evaluating Valuation Following Recent Share Price Momentum and Pipeline Expansion [Yahoo! Finance]
11/20
07:00 am
axsm
Axsome Therapeutics to Participate in Upcoming Investor Conferences
Low
Report
Axsome Therapeutics to Participate in Upcoming Investor Conferences
11/10
09:00 am
axsm
Pomerantz LLP and The Rosen Law Firm, P.A. Announce Proposed Class Action Settlement on Behalf of Purchasers of Axsome Therapeutics, Inc. Common Stock - AXSM
Low
Report
Pomerantz LLP and The Rosen Law Firm, P.A. Announce Proposed Class Action Settlement on Behalf of Purchasers of Axsome Therapeutics, Inc. Common Stock - AXSM
11/10
05:21 am
axsm
2 Monster Stocks in the Making [Yahoo! Finance]
Low
Report
2 Monster Stocks in the Making [Yahoo! Finance]
11/7
07:07 pm
axsm
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Third-Quarter Results: Here's What Analysts Are Forecasting For Next Year [Yahoo! Finance]
Low
Report
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Third-Quarter Results: Here's What Analysts Are Forecasting For Next Year [Yahoo! Finance]
11/6
11:47 am
axsm
Axsome Therapeutics (NASDAQ:AXSM) had its price target raised by analysts at Mizuho from $200.00 to $202.00. They now have an "outperform" rating on the stock.
Low
Report
Axsome Therapeutics (NASDAQ:AXSM) had its price target raised by analysts at Mizuho from $200.00 to $202.00. They now have an "outperform" rating on the stock.
11/6
07:23 am
axsm
Avenue Therapeutics Announces Acquisition of Subsidiary Baergic Bio by Axsome Therapeutics [Yahoo! Finance]
Low
Report
Avenue Therapeutics Announces Acquisition of Subsidiary Baergic Bio by Axsome Therapeutics [Yahoo! Finance]
11/6
07:00 am
axsm
Axsome Therapeutics Acquires Subtype Selective GABA-A Receptor Positive Allosteric Modulator AZD7325 for the Treatment of Epilepsy
Low
Report
Axsome Therapeutics Acquires Subtype Selective GABA-A Receptor Positive Allosteric Modulator AZD7325 for the Treatment of Epilepsy
11/4
12:09 pm
axsm
Axsome Therapeutics (NASDAQ:AXSM) had its "buy" rating reaffirmed by analysts at HC Wainwright.
Low
Report
Axsome Therapeutics (NASDAQ:AXSM) had its "buy" rating reaffirmed by analysts at HC Wainwright.
11/4
12:08 pm
axsm
Axsome Therapeutics (NASDAQ:AXSM) was given a new $196.00 price target on by analysts at Morgan Stanley.
Low
Report
Axsome Therapeutics (NASDAQ:AXSM) was given a new $196.00 price target on by analysts at Morgan Stanley.
11/4
11:54 am
axsm
Axsome Therapeutics (NASDAQ:AXSM) had its price target raised by analysts at Royal Bank Of Canada from $189.00 to $198.00. They now have an "outperform" rating on the stock.
Low
Report
Axsome Therapeutics (NASDAQ:AXSM) had its price target raised by analysts at Royal Bank Of Canada from $189.00 to $198.00. They now have an "outperform" rating on the stock.
11/4
10:53 am
axsm
Axsome Therapeutics (NASDAQ:AXSM) had its price target raised by analysts at Guggenheim from $200.00 to $205.00. They now have a "buy" rating on the stock.
Low
Report
Axsome Therapeutics (NASDAQ:AXSM) had its price target raised by analysts at Guggenheim from $200.00 to $205.00. They now have a "buy" rating on the stock.
11/4
08:43 am
axsm
Axsome Therapeutics (NASDAQ:AXSM) was given a new $157.00 price target on by analysts at Wells Fargo & Company.
Low
Report
Axsome Therapeutics (NASDAQ:AXSM) was given a new $157.00 price target on by analysts at Wells Fargo & Company.
11/4
08:09 am
axsm
Axsome Therapeutics (NASDAQ:AXSM) had its "buy" rating reaffirmed by analysts at Needham & Company LLC. They now have a $154.00 price target on the stock.
Low
Report
Axsome Therapeutics (NASDAQ:AXSM) had its "buy" rating reaffirmed by analysts at Needham & Company LLC. They now have a $154.00 price target on the stock.
11/3
07:00 am
axsm
Axsome Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update
Low
Report
Axsome Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update
10/24
12:16 pm
axsm
Axsome Therapeutics (NASDAQ:AXSM) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Axsome Therapeutics (NASDAQ:AXSM) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
10/24
11:20 am
axsm
Halper Sadeh LLC Encourages Axsome Therapeutics, Inc. Shareholders to Contact the Firm to Discuss Their Rights
Low
Report
Halper Sadeh LLC Encourages Axsome Therapeutics, Inc. Shareholders to Contact the Firm to Discuss Their Rights
10/22
07:00 am
axsm
Axsome Therapeutics to Participate in Upcoming Investor Conferences
Low
Report
Axsome Therapeutics to Participate in Upcoming Investor Conferences
10/20
08:21 am
axsm
Axsome Therapeutics (NASDAQ:AXSM) had its "overweight" rating reaffirmed by analysts at Morgan Stanley.
Medium
Report
Axsome Therapeutics (NASDAQ:AXSM) had its "overweight" rating reaffirmed by analysts at Morgan Stanley.
10/10
04:09 am
axsm
Axsome Therapeutics' Strong Growth And Expanding Pipeline: Why I Assign A Buy Rating [Seeking Alpha]
Low
Report
Axsome Therapeutics' Strong Growth And Expanding Pipeline: Why I Assign A Buy Rating [Seeking Alpha]
10/9
07:00 am
axsm
Axsome Therapeutics Recognizes Mental Illness Awareness Week Along with the National Advocacy Community
Low
Report
Axsome Therapeutics Recognizes Mental Illness Awareness Week Along with the National Advocacy Community
10/7
02:21 pm
axsm
Back Pay At Risk For Federal Workers Amid Shutdown [Forbes]
Low
Report
Back Pay At Risk For Federal Workers Amid Shutdown [Forbes]
10/7
07:00 am
axsm
Axsome Therapeutics to Report Third Quarter 2025 Financial Results on November 3
Low
Report
Axsome Therapeutics to Report Third Quarter 2025 Financial Results on November 3
10/2
05:10 pm
axsm
Piper Sandler Maintains Overweight on Axsome (AXSM), Sees Growth in AD-Agitation [Yahoo! Finance]
Low
Report
Piper Sandler Maintains Overweight on Axsome (AXSM), Sees Growth in AD-Agitation [Yahoo! Finance]
10/2
07:19 am
axsm
Axsome Therapeutics (NASDAQ:AXSM) was upgraded by analysts at B. Riley to a "strong-buy" rating.
Low
Report
Axsome Therapeutics (NASDAQ:AXSM) was upgraded by analysts at B. Riley to a "strong-buy" rating.